X0306 4 2021-06-02 0 0001847903 Centessa Pharmaceuticals plc CNTA 0001861844 GOYAL ARJUN C/O CENTESSA PHARMACEUTICALS PLC 3RD FLOOR, 1 ASHLEY RD, ALTRINCHAM CHESHIRE X0 WA14 2DT UNITED KINGDOM 1 0 0 0 Ordinary Shares 2021-06-02 4 C 0 3095909 A 3095909 I See footnote Ordinary Shares 2021-06-02 4 C 0 85909 A 85909 I See footnote Ordinary Shares 2021-06-02 4 P 0 729750 20.00 A 3825659 I See footnote Ordinary Shares 2021-06-02 4 P 0 20250 20.00 A 106159 I See footnote Series A Preferred Shares 2021-01-29 4 A 0 3095909 11.00 A Ordinary Shares 3095909 3095909 I See footnote Series A Preferred Shares 2021-01-29 4 A 0 85909 11.00 A Ordinary Shares 85909 85909 I See footnote Series A Preferred Shares 2021-06-02 4 C 0 3095909 0.00 D Ordinary Shares 3095909 0 I See footnote Series A Preferred Shares 2021-06-02 4 C 0 85909 0.00 D Ordinary Shares 85909 0 I See footnote The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date. Held by Vida Ventures II, LLC ("Vida II Main Fund"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II Main Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Held by Vida Ventures II-A, LLC ("Vida II Parallel Fund"). VV Manager II is the manager of Vida II Parallel Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split. /s/ Marella Thorell, attorney-in-fact 2021-06-04